文献速递腹部胸部技术与安全CTMR

ctDNA在胰腺导管腺癌监测中的部位特异性局限:影像可检出液体活检漏诊的肺部及局部复发

Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liquid biopsy.
PubMed 文献 · Abdom Radiol (NY) · 2026-03-20

单中心回顾性研究纳入50例切除后胰腺导管腺癌患者,评估ctDNA与影像监测复发的一致性;ctDNA与影像一致率78%,不一致11例中10例为影像阳性而ctDNA阴性,多位于肺(5例)或手术床(5例);影像复发均早于ctDNA阴性结果。

要点

  • 肺转移和手术床局部复发常表现为ctDNA阴性,阅片时不应因ctDNA阴性而放松对这两个部位的评估。
  • ctDNA阳性与淋巴结、肝、腹膜和骨转移的影像复发相关。
  • 影像复发在全部10例不一致病例中均早于ctDNA阴性检测结果。

核心结论

  • PDAC切除后ctDNA阳性与淋巴结、肝、腹膜和骨的影像复发相关,但肺和手术床的影像复发常伴ctDNA阴性;放射科医生在ctDNA阴性时仍应仔细审视后两个部位。

研究设计与样本

  • 单中心回顾性研究,纳入50例切除后PDAC患者,2015年1月至2025年2月间同时接受ctDNA检测和监测影像(胸部、腹部和盆腔CT或CT/MRI,间隔3-6个月);两名腹部放射科医生独立评估复发(新发或增大的病灶),分歧经共识解决;ctDNA复发定义为检测到肿瘤特异性突变;在患者水平评估一致性。

关键影像表现/征象

  • 不一致病灶多位于肺(n=5,中位大小0.4 cm)或手术床(n=5,中位大小2.0 cm)。
  • 10例影像复发而ctDNA阴性的病例中,影像复发均早于ctDNA阴性检测结果。
  • 1例患者ctDNA阳性但随访497天内影像未见复发。

诊断标准与关键数值

  • 患者水平:ctDNA与影像一致39/50(78%),其中22例复发、17例无复发;不一致11例,10例为影像复发而ctDNA阴性。
  • 器官水平:影像诊断的肺转移中1/6(17%)经ctDNA检出,局部复发中10/15(67%)经ctDNA检出。
  • 所有淋巴结、肝、腹膜和骨转移均经ctDNA检出。

临床应用与阅片要点

  • 放射科医生在ctDNA阴性时仍应仔细审视肺和手术床,因这两个部位的影像复发常伴ctDNA阴性。
  • ctDNA阳性提示应关注淋巴结、肝、腹膜和骨的影像复发。

局限性

  • 单中心、回顾性研究。
  • 样本量小(50例)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the concordance between circulating tumor DNA (ctDNA) and imaging in the postoperative surveillance of patients with resected pancreatic ductal adenocarcinoma (PDAC).

METHODS: This single-center, retrospective study included 50 patients with resected PDAC who underwent both ctDNA testing and surveillance imaging between January 2015 and February 2025. Imaging included CT or CT/MRI of the chest, abdomen, and pelvis at 3-6 month intervals, with ctDNA testing performed on a similar schedule. Two abdominal radiologists independently reviewed all imaging for recurrence, defined by new or enlarging lesions; discrepancies were resolved by consensus. ctDNA recurrence was defined as the detection of tumor-specific mutations. Concordance was assessed at the patient level.

RESULTS: Among 50 patients (median age 69.5 years, 33 men, 17 women), ctDNA and imaging were concordant in 39 (78%): 22 had recurrence and 17 did not. Discordance occurred in 11 patients, 10 of whom had radiologic recurrence with negative ctDNA. Most discordant lesions were located in the lung (n = 5, median size 0.4 cm) or surgical bed (n = 5, median size 2.0 cm). Radiologic recurrences preceded negative ctDNA test results in all 10 of these cases. One patient had positive ctDNA without imaging recurrence over 497 days of follow-up. At the organ level, 1/6 (17%) of lung metastases and 10/15 (67%) of local recurrences by imaging were detected by ctDNA. All lymph node, liver, peritoneal, and bone metastases were detected by ctDNA.

CONCLUSION: Positive ctDNA tests after PDAC resection correlates with radiologic recurrences in the lymph nodes, liver, peritoneum, and bones. However, radiologic recurrences in the lungs or surgical bed are commonly associated with a negative ctDNA test. Radiologists should scrutinize the latter two sites even when ctDNA tests are negative.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Elsherif SB, Shen L, Yoon L, et al. Site-specific limitations of ctDNA in PDAC surveillance: imaging detects pulmonary and local recurrence missed by liquid biopsy. Abdom Radiol (NY). 2026. PMID: 41860708. doi:10.1007/s00261-026-05470-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。